FOR IMMEDIATE RELEASE
December 13, 2022
MEDIA CONTACT:
Ilana Ostrin
212-328-3769
iostrin@hemophilia.org
Organization set to look back while moving ahead during historic year
NEW YORK — In 2023…
Spark has announced updated multi-year results from its phase 1/2 clinical trial of SPK-8011, the company’s investigational gene therapy for hemophilia A. The results were presented at the recently concluded 64th American Society of Hematology…
inSourceRX Prescription Savings
Speaker(s): Jim Christensen & Maureen Parsons
NHF's Wednesday Webinars are a free education series open to providers and community members. Register to attend and learn…
Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A
Speaker(s): Sylvia Fong
NHF's Wednesday Webinars are a free…
VWD Guidelines: Second Anniversary Update
Speaker(s): Lena Volland and Nikole Scappe
NHF's Wednesday Webinars are a free education series open to providers and community members. Register to attend and learn…
Recruitment is now open for Own Your Path- a program for young adult males with hemophilia who are currently in the transition years between 18-29. We know that maintaining adherence to a prophy regimen can have short and long -term health benefits…
Recruitment is now open for Own Your Path- a program for young adult males with hemophilia who are currently in the transition years between 18-29. We know that maintaining adherence to a prophy regimen can have short and long -term health benefits…
It’s time to lace up your running shoes! NHF is participating in the 2023 United Airlines NYC Half Marathon on Sunday, March 19, 2023. Team NHF will run 13 miles, from Brooklyn to Manhattan, raising funds and awareness for the inheritable…
Dr. von Drygalski's research focuses on better understanding the mechanisms operating the anti-fibrinolytic system and how this process works in patients with hemophilia and specifically with joint bleeding. Accelerated fibrinolysis and clot…